



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





Sarcoma Comprehensive NGS Fusion Panel

Alternative Name

NGS Comprehensive Sarcoma Fusion Profile

Methodology

Molecular

Test Description

The Sarcoma Comprehensive NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ACTB, AHRR, ALK, ASPSCR1, ATF1, ATIC, BCOR, BRAF, C11orf95, CAMTA1, CARS1, CCNB3, CDH11, CIC, CLTC, CNBP, COL1A1, COL1A2, CREB1, CREB3L1, CREB3L2, CSF1, CTNNB1, DDIT3, DUX4, EML4, EPC1, ERG, ETV1, ETV4, ETV6, EWSR1, FEV, FLI1, FOXO1, FRK, FUS, GLI1, HAS2, HEY1, HMGA2, IL2RB, ITK, JAZF1, LMNA, LPP, MEAF6, MRTFB, MYH9, MYLK, NAB2, NCOA1, NCOA2, NFATC2, NFIB, NR4A3, NTRK1, NTRK2, NTRK3, NUTM2A, NUTM2B, OMD, PAX3, PATZ1, PAX7, PBX1, PDGFB, PDGFRB, PHF1, PLAG1, POU5F1, RAD51B, RANBP2, ROS1, SEC31A, SRF, SS18, SSX1, SSX2, SSX4B, STAT6, SUZ12, SYK, TAF15, TCF12, TEAD1, TFE3, TFG, THRAP3, TPM3, TPM4, USP6, WT1, WWTR1, YAP1, YWHAE and ZNF444.

Clinical Significance

Sarcoma is a connective tissue cancer of mesenchymal origin which accounts for more than 20% of pediatric solid tumor malignancies but is rare in adults. The majority of sarcomas are classified as soft tissue sarcomas and approximately 10% are malignant bone tumors. Genomic rearrangements called translocations are present in approximately 20-30% of sarcomas and are associated with different subtypes of sarcomas. Identification of translocations can be useful for diagnosis, disease subclassification, and determining therapy. Compared to FISH, molecular detection of sarcoma translocations, as provided in this test, requires less tumor sample for a much broader and therefore more cost-effective screen.

Specimen Requirements

- **FFPE tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Storage & Transportation

Use cold pack for transporting block during summer to prevent block from melting. Slides can be packed at room temperature.

CPT Code(s)*

81456

Medicare MoIDX CPT Code(s)*

81449

New York Approved

Yes

Level of Service

Global

Turnaround Time

21 days

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 050624